---
schema_version: "secwatch.filing_event.v1"
accession: "0001612630-25-000021"
form_type: "8-K"
ticker: "JYNT"
cik: "0001612630"
company_name: "JOINT Corp"
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:38:00.760954+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Joint Corp Q2 rev $13.3M +5%, narrows loss; cuts FY system-wide sales guidance to $530-550M

## Summary
- Q2 revenue $13.3M (+5% YoY); consolidated net income $93K vs loss $3.6M; net loss from continuing ops $990K vs loss $1.7M.
- Adjusted EBITDA from continuing ops improved to $88K from loss $380K; consolidated Adj EBITDA up 52% to $3.2M.
- Refranchised 37 clinics for $11.2M, acquired NW regional developer territory for $2.8M; franchised now 92% of 967 clinics.
- Cuts FY 2025 system-wide sales guidance to $530-550M (from $550-570M); comp sales now low-single digit vs mid-single digit; raises consolidated Adj EBITDA guidance.
- Announced restatement of 2024 10-K and Q1 2025 10-Q for non-cash impairment errors; no impact on Adj EBITDA.

## SEC filing metadata
- accession: 0001612630-25-000021
- form_type: 8-K
- ticker: JYNT
- cik: 0001612630
- company_name: JOINT Corp
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1612630/000161263025000021/0001612630-25-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1612630/000161263025000021/jynt-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001612630-25-000021
- JSON: https://secwatch.observer/filing/0001612630-25-000021.json
- Plain text: https://secwatch.observer/filing/0001612630-25-000021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.